Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
10.56
-0.51 (-4.61%)
Feb 12, 2026, 1:31 PM EST - Market open
Entrada Therapeutics Employees
Entrada Therapeutics had 183 employees as of December 31, 2024. The number of employees increased by 24 or 15.09% compared to the previous year.
Employees
183
Change
24
Growth
15.09%
Revenue / Employee
$336,175
Profits / Employee
-$565,328
Market Cap
378.70M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 183 | 24 | 15.09% |
| Sep 30, 2024 | 177 | 27 | 18.00% |
| Jun 30, 2024 | 168 | 37 | 28.24% |
| Mar 31, 2024 | 160 | 30 | 23.08% |
| Dec 31, 2023 | 159 | 29 | 22.31% |
| Sep 30, 2023 | 150 | 26 | 20.97% |
| Jun 30, 2023 | 131 | 9 | 7.38% |
| Mar 31, 2023 | 130 | 16 | 14.04% |
| Dec 31, 2022 | 130 | 16 | 14.04% |
| Sep 30, 2022 | 124 | 26 | 26.53% |
| Jun 30, 2022 | 122 | 44 | 56.41% |
| Mar 31, 2022 | 114 | 36 | 46.15% |
| Dec 31, 2021 | 114 | - | - |
| Sep 30, 2021 | 98 | - | - |
| Jun 30, 2021 | 78 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Bicycle Therapeutics | 305 |
| Allogene Therapeutics | 229 |
| Absci | 157 |
| Niagen Bioscience | 104 |
| Aclaris Therapeutics | 64 |
| PepGen | 57 |
| NovaBridge Biosciences | 32 |
TRDA News
- 8 days ago - Entrada Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases - GlobeNewsWire
- 2 months ago - Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts - Seeking Alpha
- 3 months ago - Entrada Therapeutics Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Entrada Therapeutics, Inc. - Special Call - Seeking Alpha